TCM

TCG Crossover Management Portfolio holdings

AUM $4.16B Turnover 31.15%
1-Year Est. Return 983.43%
This Fund
S&P 500
This Quarter Est. Return
+25.95%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.16B
AUM Growth
+$665M
Cap. Flow
-$4.87M
Cap. Flow %
-0.12%
Top 10 Hldgs %
57.45%
Holding
61
New
12
Increased
2
Reduced
9
Closed
7
Avg Time Held
1 year
Top 10 Avg Time Held
0.8 years
Top 20 Avg Time Held
1.3 years

Top Buys

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$121M
2
AURA icon
Aura Biosciences
AURA
+$68.2M
3
TRAX icon
First Tracks Biotherapeutics
TRAX
+$54.1M
4
AVTX icon
Avalo Therapeutics
AVTX
+$36M
5
EDIT icon
Editas Medicine
EDIT
+$32.5M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$170M
2
ABVX icon
Abivax
ABVX
+$53.6M
3
FULC icon
Fulcrum Therapeutics
FULC
+$40.3M
4
TNGX icon
Tango Therapeutics
TNGX
+$35.8M
5
RVMD icon
Revolution Medicines
RVMD
+$34.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.82%
2 Financials 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TECX icon
26
Tectonic Therapeutic
TECX
$410M
$41.4M 1%
1,204,891
– –
2026 Q1
1 quarter
XNCR icon
27
Xencor
XNCR
$1.74B
$39.5M 0.95%
2,452,138
– –
2024 Q3
7 quarters
SRZN icon
28
Surrozen
SRZN
$279M
$38.2M 0.92%
1,473,101
– –
2026 Q1
1 quarter
EDIT icon
29
Editas Medicine
EDIT
$349M
$36M 0.87%
+11,111,111
New +$32.5M
2026 Q2
0 quarters
MBX icon
30
MBX Biosciences
MBX
$2.35B
$35.9M 0.86%
650,000
– –
2024 Q3
7 quarters
PHVS icon
31
Pharvaris
PHVS
$2.11B
$34.9M 0.84%
+1,008,229
New +$30.5M
2026 Q2
0 quarters
SLN icon
32
Silence Therapeutics
SLN
$558M
$33.3M 0.8%
3,033,560
– –
2022 Q3
15 quarters
IFRX icon
33
InflaRx
IFRX
$218M
$32.5M 0.78%
+14,500,000
New +$27.2M
2026 Q2
0 quarters
ALT icon
34
Altimmune
ALT
$449M
$30.4M 0.73%
+10,000,000
New +$29.9M
2026 Q2
0 quarters
JANX icon
35
Janux Therapeutics
JANX
$1.05B
$27.5M 0.66%
1,789,617
– –
2025 Q4
2 quarters
CATX icon
36
Perspective Therapeutics
CATX
$256M
$27M 0.65%
7,915,567
– –
2026 Q1
1 quarter
AGMB icon
37
AgomAb Therapeutics NV
AGMB
$428M
$26.7M 0.64%
2,053,233
– –
2026 Q1
1 quarter
BHVN icon
38
Biohaven
BHVN
$1.65B
$26.5M 0.64%
1,779,952
-2,851,365
-62% -$30.7M
2025 Q4
2 quarters
AKTS icon
39
Aktis Oncology
AKTS
$917M
$22.5M 0.54%
+696,560
New +$14.3M
2026 Q2
0 quarters
ALEC icon
40
Alector
ALEC
$210M
$20.1M 0.48%
10,000,000
– –
2025 Q4
2 quarters
FBRX icon
41
DELISTED
Forte Biosciences
FBRX
$19.6M 0.47%
+920,000
New +$21.8M
2026 Q2
0 quarters
MNPR icon
42
Monopar Therapeutics
MNPR
$491M
$18.8M 0.45%
203,327
+71,224
+54% +$4.41M
2025 Q3
3 quarters
OCUL icon
43
Ocular Therapeutix
OCUL
$1.58B
$16.2M 0.39%
1,647,752
– –
2024 Q1
9 quarters
ADCT icon
44
ADC Therapeutics
ADCT
$185M
$12.2M 0.29%
11,390,175
– –
2025 Q3
3 quarters
ALXO icon
45
ALX Oncology
ALXO
$124M
$11.7M 0.28%
5,655,487
-7,356,362
-57% -$13.2M
2026 Q1
1 quarter
TRDA icon
46
Entrada Therapeutics
TRDA
$177M
$7.8M 0.19%
1,060,230
-1,227,270
-54% -$11.8M
2021 Q4
18 quarters
CGEM icon
47
Cullinan Oncology
CGEM
$878M
$7.41M 0.18%
406,786
– –
2026 Q1
1 quarter
ARVN icon
48
Arvinas
ARVN
$446M
$5.88M 0.14%
707,098
-1,680,363
-70% -$15.7M
2025 Q3
3 quarters
KRRO icon
49
Korro Bio
KRRO
$131M
$5.49M 0.13%
416,301
– –
2025 Q3
3 quarters
RACC icon
50
Research Alliance Corp III
RACC
$92.4M
$5.35M 0.13%
+500,000
New +$5.21M
2026 Q2
0 quarters
1
2
3

Similar funds

GCM
Gates Capital Management New York $4.16B AUM 21% 1-Year Est. Return
CIC
Chilton Investment Company Stamford, Connecticut $4.17B AUM 1.75% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $4.15B AUM 31.06% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $4.15B AUM
CAM
Crake Asset Management London, United Kingdom $4.18B AUM 13.97% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $4.14B AUM 21.49% 1-Year Est. Return
CCMIC
Cardinal Capital Management Inc (Canada) Winnipeg, Manitoba, Canada $4.13B AUM 31.23% 1-Year Est. Return

TCG Crossover Management's Q2 2026 Portfolio in Review

As of Q2 2026, TCG Crossover Management held 61 positions worth $4.16B, up 19% from $3.5B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

TCG Crossover Management's Q2 2026 filing shows 12 new, 2 increased, 9 reduced and 7 closed positions. Its largest new stake was Zai Lab: 6,137,627 shares worth $117M. The largest sale was Centessa Pharmaceuticals, an estimated $170M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • TCG Crossover Management's largest Q2 2026 buy was Zai Lab: 6,137,627 shares worth $117M.
  • TCG Crossover Management added most to Avalo Therapeutics in Q2 2026, an estimated $36M increase.
  • TCG Crossover Management's biggest Q2 2026 reduction was Abivax, cutting an estimated $53.6M.
  • TCG Crossover Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $170M.
  • TCG Crossover Management's ten largest holdings make up 57% of its $4.16B portfolio in Q2 2026.
  • TCG Crossover Management opened 12 new positions and closed 7 in Q2 2026.
  • TCG Crossover Management's portfolio value rose 19% quarter-over-quarter to $4.16B.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.